NICE
NICE U-turns to recommend Sanofi Gaucher disease drug
June 2, 2017Medical Communications, Sales and Marketing Gaucher disease, NICE, Sanofi
It has been revealed that NICE has reached the decision to recommend Sanofi’s Cerdelga (eligustat) for use on the NHS …
Weight loss pill treatment rejected by NICE
May 8, 2017Medical Communications, Sales and Marketing NICE, orexigen
NICE has announced, in an Appraisal Consultation Document, that it is not able to recommend Orexigen’s Mysimba as a weight …
Pfizer offers breast cancer drug for free following NICE rejection
May 5, 2017Medical Communications, Sales and Marketing NICE, Pfizer
Following NICE’s decision rejecting Pfizer’s breast cancer therapy Ibrance (palbociclib) for use on the NHS, the manufacturer has announced that …
NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara
May 3, 2017Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease
Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …
Cancer Drug Fund roundly criticised as ‘wastage of resources’
April 28, 2017Medical Communications Cancer Drug Fund, Conservative, NHS, NICE, UK
The Cancer Drug Fund (CDF), which has now been absorbed into NICE, previous methods of funding have been fiercely criticised …
EU recommendation for Sanofi and Regeneron’s arthritis treatment
April 24, 2017Sales and Marketing Kevzara, NICE, sarilumab
Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s …
England “really is not a good place” to get cancer, BMS UK General Manager says
April 24, 2017Medical Communications, Research and Development, Sales and Marketing BMS, NICE, opdivo
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to …
NICE turns down BMS’ Opdivo for head and neck cancer
April 11, 2017Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …
NICE turns down Shire’s pancreatic cancer treatment
April 4, 2017Manufacturing and Production, Sales and Marketing NICE, Pancreatic cancer, Shire
NICE has announced its intention not to recommend the NHS use of Shire’s Onivyde (pegylated liposomal irinotecan) for the treatment …
Insider Interview: ABPI’s Paul Catchpole discusses NICE’s new fast-track appraisal system
March 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Insider Interview, NICE, Paul Catchpole, fast track
Paul Catchpole, Value and Access Director at the Association of the British Pharmaceutical Industry (ABPI), gives his thoughts on the …
NICE drug expense limit of £20 million could cause treatment delays
March 16, 2017Medical Communications, Sales and Marketing NHS England, NICE, fast-track appraisal process, rare disease
NICE has released its decision on the fast-track approval process and other changes that will be brought through at the …
FDA and NICE approve of first new hyperparathyroidism drug in 12 years
March 8, 2017Research and Development, Sales and Marketing FDA, NICE, Parsabiv, hyperparathyroidism
The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the first new treatment for patients …
Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use
March 3, 2017Medical Communications, Sales and Marketing CDF, NICE
NICE has revealed that it has reached the halfway point in its review of the old Cancer Drugs Fund (CDF) …
NICE knocks back MSD’s Keytruda for lung cancer indication
February 28, 2017Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda
MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …
NICE provisionally rejects Ipsen’s kidney cancer drug Cabometyx
February 21, 2017Manufacturing and Production, Sales and Marketing Cometriq, NICE, ipsen
NICE has announced draft guidance for Ipsen’s cancer drug Cabometyx (cabozantinib), revealing it does not recommend the drug for use on …
Latest content
FibroFind appoints Lee Borthwick as CEO
